Article
Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice.
Pharmacological research - 1 Jul 2003
Gould Todd D, Gray Neil A, Manji Husseini K
Abstract excerpt
Glycogen synthase kinase-3 (GSK-3) is an intermediary enzyme in various cellular pathways, and has been implicated in the pathophysiology and treatment of numerous diseases, including Alzheimer's disease, diabetes, and bipolar disorder. There is therefore in developing potent, selective GSK-3 inhibitors for the treatment of these devastating illnesses. A concern, however, is that the Wnt-signaling pathway-of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
